Search clinical trials for: insulin Glargine Insulin Apidra

Total 2807 results

Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, United Kingdom, France, Argentina, South Africa, Germany, Slovenia, Netherlands, Romania, North Macedonia, Mexico, Puerto Rico
University of Alberta
Sanofi

Completed

Pharmacist Intervention for Glycemic Control in The Community (RxING)

Type 2 Diabetes

Canada
University of Minnesota
Sanofi; Moran, Antoinette, M.D.

Completed

Insulin Glargine Vs Standard Insulin Therapy

Cystic Fibrosis Related Diabetes

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Time in Range | HbA1c | Type 1 Diabetes Mellitus With Diabetic Gastroparesis

China
Sanofi

Completed

Lantus in Prediabetes

Hyperglycemia | Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Poland, Slovakia, Canada, Slovenia, Greece, Czechia
Sanofi

Completed

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Halozyme Therapeutics

Completed

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
CPEX Pharmaceuticals Inc.

Completed

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus (CPEX-011)

Type 2 Diabetes

United States
Eli Lilly and Company

Completed

Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)

Diabetes Mellitus, Type 2 | Acute Myocardial Infarction

Canada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Slovakia, Spain, France, Hungary, Mexico, Russian Federation, Turkey, Czechia, Greece, Argentina
University of Maryland, Baltimore

Completed

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Northwestern University

Completed

Study of Glycemic Control on Liver Transplantation Outcomes

Hyperglycemia | Rejection | Evidence of Liver Transplantation

United States
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Ain Shams University

Not yet recruiting

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

Critical Illness | Insulin | Glycemic Control
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Diabetes Mellitus, Type 2

Poland, United States, Croatia, Spain, Slovakia, Germany, Hungary
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
The University of Texas Health Science Center,...

Completed

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis (GT-COG)

Diabetic Ketoacidosis

United States
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
University of Florida
Sanofi

Completed

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Type 1 Diabetes

United States
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
Sanofi

Completed

Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart

Type 2 Diabetes Mellitus

France
Providence Health & Services

Withdrawn

Comparison Study of Insulin Glargine and NPH Insulin

Diabetes

United States
Sanofi

Completed

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Type 2 Diabetes Mellitus

China
Mylan Inc.
Mylan GmbH

Completed

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Type 1 Diabetes Mellitus

Czechia, United States, Canada, Estonia, Germany, Hungary, Latvia, Slovakia
Mylan Inc.
Mylan GmbH

Completed

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) (INSTRIDE 1)

Type 1 Diabetes

United States, Canada, Czechia, Estonia, Germany, Hungary, Latvia, Romania, Slovakia, South Africa, United Kingdom
Sanofi

Completed

Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, United States, Australia, Hungary, Poland, Romania, Spain
Sanofi

Completed

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients (TITRATION)

Type 2 Diabetes Mellitus

Canada
Sanofi

Completed

Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes (AFICIONADO)

Diabetes Mellitus, Type 2

Argentina
GWT-TUD GmbH

Completed

Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects (GLORY)

Type 2 Diabetes

Germany
Sanofi

Completed

Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan (NEWLAN)

Diabetes Mellitus, Type 2

Jordan
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR); University of Toronto

Completed

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)

Type 2 Diabetes

Canada
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Sanofi

Terminated

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Diabetes Mellitus, Type 2

United States
Amsterdam UMC, location VUmc

Completed

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

Type 2 Diabetes Mellitus | Congestive Heart Failure

Netherlands
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation, Ukraine
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan

Search clinical trials for: insulin Glargine Insulin Apidra

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations